Antidiabetic Drugs (A10)

1.	Introduction
2.	A10A Insulins and Analogues
3.	A10B Blood Glucose-Lowering Drugs, Excl. Insulins
3.1.	A10BA Biguanides
3.2.	A10BB Sulfonylureas
3.3.	A10BC Sulfonamides (Heterocyclic)
3.4.	A10BD Combinations of Oral Blood Glucose-Lowering Drugs
3.5.	A10BF Alpha-Glucosidase Inhibitors
3.6.	A10BG Thiazolidinediones
3.7.	A10BH Dipeptidyl Peptidase 4 (DPP-4) Inhibitors
3.8.	A10BJ Glucagon-Like Peptide-1 (GLP-1) Analogues
3.9.	A10BK Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors
3.10.	A10BX Other Blood Glucose-Lowering Drugs, Excl. Insulins
4.	A10X Other Drugs Used in Diabetes

References

1 Guidelines: NICE (National Institute for Health and Care Management) (2015) https://www.nice.org.uk/guidance/ng28/chapter/1-Recommendations (accessed 6 March 2018)
Google Scholar
2 Inzucchi, S.E. et al. (2015) Management of hyperglycemia in type 2 diabetes. Diabetes Care 38, 140–149.
10.2337/dc14-2441
PubMed Web of Science® Google Scholar
3 Pfeiffer, A.F.H., Klein H.H. (2014) The treatment of type 2 diabetes. Dtsch. Ärztebl. Int. 111, 69–82.
PubMed Web of Science® Google Scholar
4 Edmondson, S.D., Weber A.E., Elliott, J., Roth, B.D., Wexler, R.R. (2015) Cardiovascular and metabolic diseases: 50 years of progress. Ann. Rep. Med. Chem. 50, 83–117.
Google Scholar
5 Johnson, I.S. (1983) Human insulin from recombinant DNA technology. Science 219, 632–637.
10.1126/science.6337396
CAS ADS PubMed Web of Science® Google Scholar
6 Gilroy, C.A., Luginbuhl K.M., Chilkoti, A. (2016) Controlled release of biologics for the treatment of type 2 diabetes. J. Control. Release 240, 151–164.
Google Scholar
7 Hilgenfeld, R., Seipke, G., Berchtold, H., Owens, D.R. (2014) The evolution of insulin glargine and its continuing contribution to diabetes care. Drugs 74, 911–927.
10.1007/s40265-014-0226-4
CAS PubMed Web of Science® Google Scholar
8 Genentech Inc. (1979) US 4 356 270, US-prior. 5.11.1979.
Google Scholar
9 Genentech Inc. (1979) US 4 366 246, US-prior. 5.11.1979.
Google Scholar
10 Genentech Inc. (1982) US 4 431 739, US-prior. 30.7.1982.
Google Scholar
11 Eli Lilly (1982) US 4 559 302, US-prior. 1.11.1982.
Google Scholar
12 Goeddel, D.V. et al. (1979) Expression in Escherichia coli of chemically synthesized genes for human insulin. Proceed. Natl. Acad. Soc. 76, 106–10.
10.1073/pnas.76.1.106
CAS ADS PubMed Web of Science® Google Scholar
13 Eli Lilly (1989) EP 383 472, US-prior. 9.2.1989, 4.8.1989.
Google Scholar
14 Eli Lilly (1994) EP 692 489, EP-prior. 16.6.1994.
Google Scholar
15 Eli Lilly (1994) US 5 461 031, US-prior. 16.6.1994.
Google Scholar
16 Eli Lilly (1994) US 5 474 978, US-prior. 16.6.1994.
Google Scholar
17 Eli Lilly (1995) EP 735 048, EP-prior. 31.3.1995.
Google Scholar
18 Eli Lilly (1997) WO 9 856 406, US-prior. 13.6.1997.
Google Scholar
19 Howey, D.C., Bowsher, R.R., Brunelle, R.L., Woodworth J.R. (1994) [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 43, 396–402.
10.2337/diab.43.3.396
CAS PubMed Web of Science® Google Scholar
20 NovoNordisk (1985) US 5 618 913, DK-prior. 30.8.1985, 14.10.1985.
Google Scholar
21 NovoNordisk (1985) EP 214 826, EP-prior. 30.8.1985, 14.10.1985.
Google Scholar
22 NovoNordisk (1996) US 5 866 538, DK-prior. 20.6.1996.
Google Scholar
23 NovoNordisk (1993) WO 9 500 550, DK-prior. 21.6.1993, 28.9.1993 US.
Google Scholar
24 Hoechst Marion Roussel (1997) EP 885 961, EP-prior. 20.6.1997.
Google Scholar
25 Aventis (1997) US 06 221 633, DE-prior. 20.6.1997.
Google Scholar
26 Aventis (2001) WO 02 076 495, DE-prior. 23.3.2001.
Google Scholar
27 Hoechst AG (1988) EP 368 187, EP-prior. 8.11.1988.
Google Scholar
28 Hoechst AG (1988) US 6 100 376, DE-prior. 8.11.1988.
Google Scholar
29 Hoechst Marion Roussel (1998) WO 9 964 598, DE-prior. 6.6.1998.
Google Scholar
30 Aventis (2002) WO 03 105 888, DE-prior. 18.6.2002.
Google Scholar
31 Aventis (2002) US 7 476 652, DE-prior. 18.6.2002.
Google Scholar
32 Aventis (2002) US 7 713 930, DE-prior. 18.6.2002.
Google Scholar
33 Sanofi (2010) WO 2011 144 673, EP-prior. 19.5.2010, 13.7.2010, 10.2.2011.
Google Scholar
34 NovoNordisk (1993) US 5 750 497, DK-prior. 17.9.1993.
Google Scholar
35 NovoNordisk (1993) US 6 011 007, DK-prior. 17.9.1993.
Google Scholar
36 NovoNordisk (1993) US 06 869 930, DK-prior. 17.9.1993.
Google Scholar
37 NovoNordisk (2003) WO 2 005 047 508, DK-prior. 14.11.2003.
Google Scholar
38 NovoNordisk (1996) US 5 866 538, DK-prior. 20.6.1996.
Google Scholar
39 NovoNordisk (2003) WO 2 00 5012 347, DK-prior. 5.8.2003, 14.8.2003,US.
Google Scholar
40 Witters, L.A. (2001) The blooming of the French lilac. J. Clin. Invest. 108, 1105–1107.
10.1172/JCI14178
CAS PubMed Web of Science® Google Scholar
41 Ferrannini, E. (2014) The target of metformin in type 2 diabetes. New Engl. J. Med. 371, 1547–1548.
10.1056/NEJMcibr1409796
CAS PubMed Web of Science® Google Scholar
42 Aron S.A.R.L. (1975) FR 2 322 860, FR-prior. 5.9.1975.
Google Scholar
43 Shapiro, S.L., Parrino, V.A., Freedman, L. (1959) Hypoglycemic Agents. III. N1-Alkyl- and Aralkylbiguanides. J. Am. Chem. Soc. 81, 3728–3736.
10.1021/ja01523a060
CAS Web of Science® Google Scholar
44 Deacon, C.F., Lebovitz, H.E. (2016) Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes. Metab. 18, 333–347.
10.1111/dom.12610
CAS PubMed Web of Science® Google Scholar
45 Hoechst AG (1966) DE 128 837, CA-prior. 21.7.1966.
Google Scholar
46 Hoechst AG (1965) US 3 454 635, DE-prior. 2.12.1965.
Google Scholar
47 Aumüller, W. et al. (1966) Ein neues hochwirksames orales Antidiabeticum. Arzneim.-Forsch. 16, 1640–1641.
CAS PubMed Web of Science® Google Scholar
48 Pfizer (1958) US 3 013 072, US-prior. 1958.
Google Scholar
49 Pfizer (1957) US 3 349 124, US-prior. 20.5.1957.
Google Scholar
50 Ruschig, H., Korger, G., Aumüller, W., Hagner, H. Weyer, R. (1958) Neue peroral wirksame blutzuckersenkende Substanzen. Arzneim.-Forsch. 8, 448–454.
CAS PubMed Web of Science® Google Scholar
51 Upjohn Co. (1955) Hoechst; US 2 968 158, DE-prior. 8.8.1955.
Google Scholar
52 Hoechst AG (1955) DE 974 062, DE-prior. 9.8.1955.
Google Scholar
53 Hoffmann-La Roche (1966) DE 1 695 201, CH-prior. 28.10.1966.
Google Scholar
54 Hoffmann-La Roche (1968) US 3 654 357, CH-prior. 26.4.1968.
Google Scholar
55 Bretschneider, H., Hohenlohe-Oehringen, K., Graßmayr, K. (1969) Arylsulfonylureido- und Arylsulfonylamidoacyl-derivate von Oxy- und Oxo-cycloalkanen als potentielle Antidiabetica. Monatshefte für Chemie 100, 2133–2135.
Google Scholar
56 Upjohn Co. (1959) US 3 063 903, US-prior. 9.6.1959.
Google Scholar
57 Wright, J.B., Willette, R.E. (1962) Antidiabetic agents. N4-arylsulfonylsemicarbazides. J. Med. Pharm. Chem. 5, 815–822.
10.1021/jm01239a016
CAS Web of Science® Google Scholar
58 Boehringer Mannh. (1953) US 2 907 692, DE-prior. 11.2.1953.
Google Scholar
59 Carlo Erba (1969) DE 2 012 138, I-prior. 26.3.1969.
Google Scholar
60 Carlo Erba (1969) US 3 669 966, I-prior. 26.3.1969.
Google Scholar
61 Boehringer Ingelheim (1970) US 3 708 486, DE-prior. 5.1.1970, 17.4.1969.
Google Scholar
62 Science Union (1966) FR 1 510 714, UK-prior. 10.2.1966.
Google Scholar
63 Science Union (1966) US 3 501 495, UK-prior. 10.2.1966.
Google Scholar
64 Bayer AG (1967) DE 1 670 952, DE-prior. 25.11.1967.
Google Scholar
65 Bayer AG (1967) US 3 668 215, DE-prior. 25.11.1967.
Google Scholar
66 Hoechst AG (1979) US 4 378 785, DE-prior. 19.12.1979.
Google Scholar
67 Hoechst AG (1979) DE 2 951 135, DE-prior. 19.12.1979.
Google Scholar
68 Hoechst AG (1993) DE 4 336 159, DE-prior. 22.1.1993.
Google Scholar
69 Weyer, R., Hitzel V. (1988) Acylureidoalkylphenylsulfonylureas with blood glucose lowering efficacy. Arzneim.-Forsch. 38, 1079–1080.
CAS PubMed Web of Science® Google Scholar
70 Tanwar, D.K., Surendrabhai, V.R., Gill, M.S. (2017) An efficient and practical process for the synthesis of glimepiride. Synlett 18, 2495–2498 (and refs. therein).
Google Scholar
71 Eli Lilly (1960) US 3 320 312, US-prior. 28.4.1960.
Google Scholar
72 Marshall, F.J., Sigal, M.V., Sullivan, H.R., Cesnik, C., Root, M.A. (1963) Further studies on N-arylsulfonyl-N'-alkylureas. J. Med. Chem. 6, 60–63.
10.1021/jm00337a014
CAS PubMed Web of Science® Google Scholar
73 Schering AG (1961) DE 1 445 142, DE-prior. 23.2.1961.
Google Scholar
74 Schering AG (1961) US 3 275 635, DE-prior. 18.10.1960, 22.2.1961, 23.2.1961.
Google Scholar
75 Abdulsalim, S., Vayalil, M.P., Miraj, S.S. (2016) New fixed dose chemical combinations: the way forward for better diabetes type II management? Expert Opin. Pharmacother. 17, 2207–2214.
10.1080/14656566.2016.1241235
Google Scholar
76 Harris, S.B. (2016) The power of two: an update on fixed-dose combinations for type 2 diabetes. Exp. Rev. Clin. Pharmacology 9, 1453–1462.
10.1080/17512433.2016.1221758
Google Scholar
77 SmithKline Beecham (1998) WO 9 857 634, UK-prior. 18.6.1997, 25.3.1998.
Google Scholar
78 SmithKline Beecham (1998) WO 9 857 649, UK-prior. 18.6.1997, 27.3.1998.
Google Scholar
79 Takeda Chem. (1995) EP 861 666, JP-prior. 20.6.1995.
Google Scholar
80 Takeda Chem. (2004) WO 2 005 099 760, JP-prior. 14.4.2004.
Google Scholar
81 Takeda Chem. (2003) WO 2 005 041 962, JP-prior. 31.10.2003.
Google Scholar
82 Merck Sharp & Dohme Ltd (2008) WO 2 009 099 734, US-prior. 5.2.2008.
Google Scholar
83 Merck Sharp & Dohme Ltd (2008) WO 2 009 111 200, US-prior. 4.3.2008.
Google Scholar
84 Novartis AG (2004) WO 2 005 117 861, US-prior. 4.6.2004, 28.8.2004.
Google Scholar
85 Novartis AG (2005) WO 2 007 041 053, US-prior. 25.9.2005.
Google Scholar
86 Takeda Pharm. (2007) WO 2 008 093 882, JP-prior. 1.2.2007.
Google Scholar
87 Bristol-Myers Squibb (2000) WO 200 168 603, US-prior. 10.3.2000.
Google Scholar
88 Bristol-Myers Squibb (2004) US 8 628 799, US-prior. 25.5.2004.
Google Scholar
89 Boehringer Ingelheim (2011) WO 2 012 120 040, EP-prior. 7.3.2011, 15.3.2011.
Google Scholar
90 Boehringer Ingelheim (2017) WO 2 017 211 979, EP-prior. 10.6.2016, 1.2.2017.
Google Scholar
91 Merck Sharp & Dohme Ltd. (2009) WO 2 010 147 768, US-prior. 15.6.2009, 6.11.2009.
Google Scholar
92 Merck Sharp & Dohme Ltd. (2009) WO 2 011 049 773, US-prior. 23.10.2009.
Google Scholar
93 Takeda Pharm. (2006) WO 2 007 033 266, US-prior. 14.9.2005, 15.5.2006.
Google Scholar
94 Takeda Pharm. (2007) WO 2 009 011 451, JP-prior. 19.7.2007.
Google Scholar
95 Novo Nordisk (2006) WO 2 008 037 807, EP-prior. 29.6.2006.
Google Scholar
96 Bristol-Myers Squibb (2002) WO 03 099 836, US-prior. 20.5.2002.
Google Scholar
97 Bristol-Myers Squibb (2001) US 6 936 590, US-prior. 13.3.2001.
Google Scholar
98 Bristol-Myers Squibb, Astra-Zeneca (2009) WO 2 010 138 535, US-prior. 27.5.2009.
Google Scholar
99 Bristol-Myers Squibb, Astra-Zeneca (2009) WO 2 011 060 290, US-prior. 13.11.2009.
Google Scholar
100 Bristol-Myers Squibb, Astra-Zeneca (2009) WO 2 011 060 256, US-prior. 13.11.2009.
Google Scholar
101 Janssen Pharm. (2010) WO 2 011 005 811, US-prior. 8.7.2009, 6.7.2010.
Google Scholar
102 LG Life Sciences (2012) WO 2 014 058 188, Korea-prior. 8.10.2012.
Google Scholar
103 Boehringer Ingelheim (1997) WO 2 008 055 940, US-prior. 8.11.1997.
Google Scholar
104 Boehringer Ingelheim (2009) WO 2 010 092 125, US-prior. 13.2.2009.
Google Scholar
105 Boehringer Ingelheim (2009) WO 2 011 039 337, US-prior. 2.10.2009.
Google Scholar
106 Boehringer Ingelheim (1997) WO 2 008 055 940, US-prior. 8.11.1997.
Google Scholar
107 Boehringer Ingelheim (2009) WO 2 010 092 125, US-prior. 13.2.2009.
Google Scholar
108 Boehringer Ingelheim (2012) WO 2 010 092 125, US-prior. 7.3.2012.
Google Scholar
109 Bristol-Myers Squibb (2000) WO 200 127 128, US-prior. 12.10.1999, 5.4.2000.
Google Scholar
110 Bristol-Myers Squibb (2000) WO 200 168 603, US-prior. 10.3.2000.
Google Scholar
111 Bristol-Myers Squibb (2002) WO 03 099 836, US-prior. 20.5.2002.
Google Scholar
112 Bristol-Myers Squibb (2003) US 6 936 590, US-prior. 19.6.2003.
Google Scholar
113 Bristol-Myers Squibb (2004) WO 2 005 117 841, US-prior. 28.5.2004.
Google Scholar
114 Bristol-Myers Squibb (2007) WO 2 008 116 179, US-prior. 22.3.2007.
Google Scholar
115 Pfizer (2008) US 8 080 580, US-prior. 24.8.2008.
Google Scholar
116 Pfizer (2009) WO 2 010 023 594, US-prior. 28.8.2008, 21.7.2009.
Google Scholar
117 Merck Sharp Dohme Ltd (2013) WO 2 014 159 151, US-prior. 14.4.2013, 7.10.2013, 5.12.2013.
Google Scholar
118 Merck Sharpe Dome Ltd (2001) WO 2 003 004 498, US-prior. 6.7.2001.
Google Scholar
119 Pfizer (2009) WO 2 010 023 594, US-prior. 28.8.2008, 21.7.2009.
Google Scholar
120 Bayer AG (1973) US 4 062 950, DE-prior. 22.9.1973.
Google Scholar
121 Bayer AG (1985) US 4 904 769, DE-prior. 13.12.1985.
Google Scholar
122 Bayer AG (1985) DE 3 543 999, DE-prior. 13.12.1985.
Google Scholar
123 Bayer AG (1984) DE 3 439 008, DE-prior. 25.10.1984.
Google Scholar
124 Boedeker, B.G.D. (1996) Bioprocess technologies depending on the molecular-structure of pharmaceutical products. Chimia 50, 412–413.
Google Scholar
125 Schmidt, D.D. et al. (1977) Alpha-glucosidase inhibitors. New complex oligosaccharides of microbial origin. Naturwissenschaften 64, 535–536.
10.1007/BF00483561
CAS ADS PubMed Web of Science® Google Scholar
126 Ogawa, S., Shibata, Y. (1988) Total synthesis of acarbose and adiposin-2. J. Chem. Soc., Chem. Comm. 9, 605–606.
Google Scholar
127 Bayer AG (1986) DE 3 611 841, DE-prior. 9.4.1986.
Google Scholar
128 Bayer AG (1977) US 4 639 436, DE-prior. 27.8.1977, 24.12.1977.
Google Scholar
129 Bayer AG (1979) DE 2 758 025 DE-prior. 24.12.1977.
Google Scholar
130 Bayer AG (1981) EP 49 858, DE-prior. 15.10.1981.
Google Scholar
131 Takeda Pharm. (1981) EP 56 194, JP-prior. 5.1.1981, 2.5.1981, 6.10.2981.
Google Scholar
132 Horii, S. et al. (1986) Synthesis and alpha-D-glucosidase inhibitory activity of N-substituted valiolamine derivatives as potential oral antidiabetic agents. J. Med. Chem. 29, 1038–46.
10.1021/jm00156a023
CAS PubMed Web of Science® Google Scholar
133 Sankyo Co. (1983) EP 139 421, JP-prior. 30.8.1983.
Google Scholar
134 Sankyo Co. (1983) US 4 572 912, JP-prior. 30.8.1983.
Google Scholar
135 Sankyo Co. (1985) EP 207 581, JP-prior. 26.2.1985.
Google Scholar
136 Beecham Group (1988) US 5 002 953, UK-prior. 4.9.1987, 30.11.1987, 4.2.1988.
Google Scholar
137 Beecham Group (1987) EP 306 228, UK-prior. 4.9.1987.
Google Scholar
138 Beecham Group (1991) WO 9 310 254, UK-prior. 19.11.1991.
Google Scholar
139 Beecham Group (1988) US 5 646 169, UK-prior. 4.9.1987, 30.11.1987, 4.2.1988.
Google Scholar
140 Beecham Group (1988) EP 306 228, UK-prior. 4.9.1987, 30.11.1987, 4.2.1988.
Google Scholar
141 Cantello, B.C.C. et al. (1994) The synthesis of BRL-49653 – a novel potent antihyperglycemic agent. Bioorg. & Med. Chem. Lett. 4, 1181–1184.
10.1016/S0960-894X(01)80325-5
CAS Web of Science® Google Scholar
142 Cantello, B.C.C. et al. (1994). w-Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J. Med. Chem. 37, 3977–3978.
10.1021/jm00049a017
CAS PubMed Web of Science® Google Scholar
143 Takeda Chem. Ind. (1985) US 4 687 777, JP-prior. 19.1.1985.
Google Scholar
144 Takeda Chem. Ind. (1985) EP 193 256, JP-prior. 19.1.1985.
Google Scholar
145 Sohda, T. et al. (1990) Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones. Arzneim.-Forsch. 40, 37–42.
CAS PubMed Web of Science® Google Scholar
146 Madivada, L.R. et al. (2009) An improved process for pioglitazone and its pharmaceutically acceptable salt. Org. Proc. Res. & Dev. 13, 1190–1194 (and refs. therein).
Google Scholar
147 Scheen, A.J. (2012) Review of gliptins in 2011. Exp. Op. Pharmacotherapy 13, 81–99.
10.1517/14656566.2012.642866
CAS PubMed Web of Science® Google Scholar
148 Deacon, C.F., Holst, J.J. (2013) DPP-4 inhibitors for the treatment of T2D: comparison, efficacy and safety. Expert Opin. Pharmacother. 14, 2047–2058.
10.1517/14656566.2013.824966
CAS PubMed Web of Science® Google Scholar
149 Deacon, C.F., Lebovitz, H.E. (2016) Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes. Metab. 18, 333–347.
10.1111/dom.12610
CAS PubMed Web of Science® Google Scholar
150 Merck Sharp & Dohme Ltd. (2003) WO 2 004 085 661, US-prior. 24.3.2003.
Google Scholar
151 Merck Sharp & Dohme Ltd. (2003) WO 2 005 003 135, US-prior. 24.6.2003.
Google Scholar
152 Merck Sharp & Dohme Ltd. (2004) WO 2 006 065 826, US-prior. 15.12.2004.
Google Scholar
153 Kim, D. et al. (2005) (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 48, 141–151.
10.1021/jm0493156
CAS PubMed Web of Science® Google Scholar
154 Hansen, K.B. et al. (2005) First generation process for the preparation of the DPP-IV inhibitor sitagliptin. Org. Proc. Res. & Dev. 9, 634–639.
10.1021/op0500786
CAS Web of Science® Google Scholar
155 Novartis AG (1998) WO 2 000 034 241, US-prior. 10.12.1998.
Google Scholar
156 Novartis AG (1998) US 6 166 063, US-prior. 10.12.1998.
Google Scholar
157 Villhauer, E.B. et al. (2003) 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem. 46, 2774–2789.
10.1021/jm030091l
CAS PubMed Web of Science® Google Scholar
158 Bristol-Myers Squibb (2000) US 6 395 767, US-prior. 10.3.2000.
Google Scholar
159 Bristol-Myers Squibb (2005) US 6 995 183, US-prior. 17.2.2005.
Google Scholar
160 Augeri, D.J. et al. (2005) Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 48, 5025–5037.
10.1021/jm050261p
CAS PubMed Web of Science® Google Scholar
161 Savage, S.A. et al. (2009) Preparation of saxagliptin, a novel DPP-IV inhibitor. Org. Proc. Res. & Dev. 13, 1169–1176.
10.1021/op900226j
CAS Web of Science® Google Scholar
162 Syrrx (2004) WO 2 005 095 381, US-prior. 15.3.2004.
Google Scholar
163 Takeda Pharm. Comp. (2005) WO 2 007 033 266, US-prior. 14.9.2005.
Google Scholar
164 Takeda Pharm. Comp. (2005) WO 2 007 035 629, US-prior. 16.9.2005.
Google Scholar
165 Feng, J. et al. (2007) Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J. Med. Chem. 50, 2297–2300.
10.1021/jm070104l
CAS PubMed Web of Science® Google Scholar
166 Boehringer Ingelheim (2002) WO 2 004 018 468, DE-prior. 21.8.2002.
Google Scholar
167 Boehringer Ingelheim (2002) DE 10 238 243, DE-prior. 21. 8.2002.
Google Scholar
168 Boehringer Ingelheim (2002) US 7 407 955, DE-prior. 21.8.2002.
Google Scholar
169 Boehringer Ingelheim (2002) US 8 119 648, DE-prior. 21. 8.2002.
Google Scholar
170 Boehringer Ingelheim (2002) US 8 178 541, DE-prior. 21. 8.2002.
Google Scholar
171 Eckhardt, M. et al. (2007) 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 50, 6450–6453.
10.1021/jm701280z
CAS PubMed Web of Science® Google Scholar
172 LG Life Sciences (2005) WO 2 006 104 356, Korea-prior. 1.4.2005.
Google Scholar
173 LG Life Sciences (2010) WO 2 012 060 590, Korea-prior. 1.11.2010.
Google Scholar
174 Dong-A Pharm. (2007) WO 2 008 130 151, Korea-priority date 19.4.2007.
Google Scholar
175 Dong-A Pharm. (2009) WO 2 010 114 291, Korea-prior. 30.3.2009.
Google Scholar
176 Dong-A Pharm. (2007) WO 2 010 114 292, Korea-prior. 19.4.2007.
Google Scholar
177 Kim, H.J. et al. (2011) Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett. 21, 3809–3812.
10.1016/j.bmcl.2011.04.029
CAS PubMed Web of Science® Google Scholar
178 Gilroy, C.A., Luginbuhl K.M., Chilkoti, A. (2016) Controlled release of biologics for the treatment of type 2 diabetes. J. Contr. Rel. 240, 151–164.
10.1016/j.jconrel.2015.12.002
Google Scholar
179 Manandhar, B., Ahn, J.-M. (2015) Glucagon-like peptide-1 (GLP-1) analogues: recent advances, new possibilities and therapeutic implications. J. Med. Chem. 58, 1020–1037.
10.1021/jm500810s
CAS PubMed Web of Science® Google Scholar
180 Lorenz, M., Evers A., Wagner M. (2013) Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity. Bioorg. Med. Chem. Lett. 23, 4011–4018.
10.1016/j.bmcl.2013.05.022
CAS PubMed Web of Science® Google Scholar
181 Meier, J.J. (2012) GLP-1 receptor agonists for the individualized therapy of type 2 diabetes mellitus. Nat. Rev. Endocrinology 8, 728–742.
10.1038/nrendo.2012.140
CAS PubMed Web of Science® Google Scholar
182 Madsbad, S. (2016) Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diab. Ob. Metab. 18, 317–332.
10.1111/dom.12596
CAS PubMed Web of Science® Google Scholar
183 J. Eng (1993) US 5 424 286, US-prior. 24.5.1993.
Google Scholar
184 Amylin Pharm. Inc. (1996) US 6 858 576, US-prior. 8.8.1996.
Google Scholar
185 Amylin Pharm. Inc. (1997) US 6 956 026, US-prior. 7.1.1997.
Google Scholar
186 Amylin Pharm. Inc. (2000) US 6 902 744, US-prior. 14.1.2000.
Google Scholar
187 Amylin Pharm. Inc. (2000) US 6 872 700, US-prior. 14.1.2000.
Google Scholar
188 Göke, R. et al. (1993) Exendin-4 Is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. J. Biol. Chem. 268, 19650–19655.
CAS PubMed Web of Science® Google Scholar
189 Novo Nordisk (1993) WO 9 517 510, DK-prior. 23.12.1993.
Google Scholar
190 Novo Nordisk (1996) WO 9 808 871, DK-prior. 30.8.1996.
Google Scholar
191 Novo Nordisk (1996) US 6 458 924, DK-prior. 30.8.1996.
Google Scholar
192 Novo Nordisk (1996) US 7 235 627, DK-prior. 30.8.1996.
Google Scholar
193 Novo Nordisk (1998) WO 9 943 707, DK-prior. 27.2.1998.
Google Scholar
194 Knudsen, L.B. et al. (2000) Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. 43, 1664–1669.
10.1021/jm9909645
CAS PubMed Web of Science® Google Scholar
195 Zealand Pharma (1999) WO 2 001 004 156, EP-prior. 12.7.1999, US, 9.8.1999.
Google Scholar
196 Zealand Pharma (2002) US 7 544 657, US-prior. 2.10.2002.
Google Scholar
197 Glaxo-SmithKline (2011) WO 2 012 109 429, US-prior. 9.2.2011.
Google Scholar
198 Bush, M.A. et al. (2009) Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes. Metab. 11, 498–505.
10.1111/j.1463-1326.2008.00992.x
CAS PubMed Web of Science® Google Scholar
199 Matthews, J.E. et al. (2008) Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J. Clin. Endocr. & Metab. 93, 4810–4817
10.1210/jc.2008-1518
CAS PubMed Web of Science® Google Scholar
200 Glaesner, W. et al. (2010) Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diab. Metab. Res. Rev. 26, 287–296.
10.1002/dmrr.1080
CAS PubMed Web of Science® Google Scholar
201 Novo Nordisk (2005) WO 2 006 097 537, DK-prior. 18.3.2005.
Google Scholar
202 Lau, J. et al. (2015) Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J. Med. Chem. 58, 7370–7380.
10.1021/acs.jmedchem.5b00726
CAS PubMed Web of Science® Google Scholar
203 Koepsell, H. (2017) The Na⁺-d-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer. Pharm. & Therap. 170, 148–165.
10.1016/j.pharmthera.2016.10.017
Google Scholar
204 Mudaliar, S., Polidori, D., Zambrowicz, B., Henry R.R. (2015) Sodium–glucose cotransporter inhibitors: Effects on renal and intestinal glucose transport from bench to bedside. Diabetes Care 38, 2344–2353.
10.2337/dc15-0642
CAS PubMed Web of Science® Google Scholar
205 Washburn, W.N. (2014) Forxiga (Dapagliflozin), a potent selective SGLT2 inhibitor for the treatment of diabetes. Ann. Rep. Med. Chem. 49, 363–382.
Google Scholar
206 Bristol-Myers Squibb (1999) US 6 414 126, US-prior. 12.10.1999.
Google Scholar
207 Bristol-Myers Squibb (1999) US 6 515 117, US-prior. 12.10.1999.
Google Scholar
208 Bristol-Myers Squibb (2003) US 7 375 213, US-prior. 3.1.2003.
Google Scholar
209 Bristol-Myers Squibb (2007) US 7 851 502, US-prior. 22.3.2007.
Google Scholar
210 Bristol-Myers Squibb (2007) US 8 221 786, US-prior. 22.3.2007.
Google Scholar
211 Bristol-Myers Squibb (2007) US 8 361 972, US-prior. 22.3.2007.
Google Scholar
212 Bristol-Myers Squibb (2007) US 8 716 251, US-prior. 22.3.2007.
Google Scholar
213 Meng, W. et al. (2008) Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 51, 1145–1149.
10.1021/jm701272q
CAS PubMed Web of Science® Google Scholar
214 Tanabe Pharma Corp. (2003) WO 2 005 012 326, JP-prior. 1.8.2003.
Google Scholar
215 Mitsubishi Tanabe Pharma Corp. (2006) WO 2 008 069 327, JP-prior. 4.12.2006.
Google Scholar
216 Mitsubishi Tanabe Pharma Corp. (2006) US 7 943 582, JP-prior. 4.12.2006.
Google Scholar
217 Janssen Pharmac., Mitsubishi Tanabe Pharma Corp. (2007) WO 2 009 035 969, US-prior. 10.9.2007.
Google Scholar
218 Janssen Pharmac. (2011) WO 2 012 140 120, US-prior. 13.4.2011.
Google Scholar
219 Nomura, S. et al. (2010) Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J. Med. Chem. 53, 6355–6360.
10.1021/jm100332n
CAS PubMed Web of Science® Google Scholar
tab. Res. Rev. 26, 287–296.
Google Scholar
220 Boehringer Ingelheim (2005) WO 2 006 117 359, EU-prior. 3.5.2005, 19.8.2005.
Google Scholar
221 Boehringer Ingelheim (2004) US 7 579 449, DE-prior. 16.3.2004, 18.8.2004, 16.12.2004.
Google Scholar
222 Boehringer Ingelheim (2004) WO 2 006 120 208, DE-prior. 10.5.2005, 23.8. 2005, 15.9.2005.
Google Scholar
223 Boehringer Ingelheim (2005) US 7 713 938, EU-prior. 3.5.2005, 19.8.2005.
Google Scholar
224 Wang, X. et al. (2014) Efficient synthesis of empagliflozin, an inhibitor of SGLT-2, utilizing an AlCl3-promoted silane reduction of a β-glycopyranoside. Org. Lett. 16, 4090–4093.
10.1021/ol501755h
CAS PubMed Web of Science® Google Scholar
225 Pfizer (2008) US 8 080 580, US-prior. 24.8.2008.
Google Scholar
226 Pfizer (2009) WO 2 010 023 594, US-prior. 28.8.2008, 21.7.2009.
Google Scholar
227 Merck Sharp Dohme Ltd (2013) WO 2 014 159 151, US-prior. 14.4.2013, 7.10.2013, 5.12.2013.
Google Scholar
228 Mascitti, V. et al. (2011) Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. J. Med. Chem. 54, 2952–2960.
10.1021/jm200049r
CAS PubMed Web of Science® Google Scholar
229 Bernhardson, D. et al. (2014) Development of an early-phase bulk enabling route to sodium-dependent glucose cotransporter 2 inhibitor ertugliflozin. Org. Proc. Res. Dev. 18, 57–65.
10.1021/op400289z
Google Scholar
230 Tanabe Seyaku Co. (2003) WO 2 005 012 326, US-prior. 1.8.2003.
Google Scholar
231 Tanabe Seyaku Co. (2003) US 20 050 233 988, US-prior. 1.8.2003.
Google Scholar
232 Astellas Pharma, Kotobuki Pharmac. (2006) WO 2 007 114 475, JP-prior. 5.4.2006.
Google Scholar
233 Astellas Pharma, Kotobuki Pharmac. (2006) WO 2 008 075 736, US-prior. 21.12.2006.
Google Scholar
234 Imamura, M. et al. (2012) Discovery of ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. Bioorg. Med. Chem. 20, 3263–3279.
10.1016/j.bmc.2012.03.051
CAS PubMed Web of Science® Google Scholar
235 Guardado-Mendoza, R., Prioletta, A., Jiménez-Ceja, L.M., Sosale, A., Folli, F. (2013) The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus. Arch. Med. Sci. 9, 936–943.
10.5114/aoms.2013.34991
CAS PubMed Web of Science® Google Scholar
236 Thomae GmbH (1985) US 5 216 167, DE-prior. 30.12.1983, 25.6.1985. 1.7.1985.
Google Scholar
237 Thomae GmbH (1991) WO 9 300 337, EP-prior. 21.6.1991.
Google Scholar
238 Grell, W. et al. (1998) Repaglinide and related hypoglycemic benzoic acid derivatives. J. Med. Chem. 41, 5219–5246.
10.1021/jm9810349
PubMed Web of Science® Google Scholar
239 Ajinomoto (1985) EP 196 222, JP-prior. 27.3.1985.
Google Scholar
240 Shinkai, H. et al. (1989) N-(cyclohexylcarbonyl)-D-phenylalanines and related compounds. A new class of oral hypoglycemic agents. J. Med. Chem. 32, 1436–1441.
10.1021/jm00127a006
CAS PubMed Web of Science® Google Scholar
241 Amylin Pharmaceuticals (1991) WO 9 310 146, US-prior. 19.11.1991.
Google Scholar
242 Science Union (1966) FR 1 517 587, UK-prior. 15.4.1966.
Google Scholar
243 Science Union (1966) DE 1 593 991, UK-prior. 15.4.1966.
Google Scholar
244 Science Union (1966) US 3 607 909, US-prior. 15.4.1966.
Google Scholar
245 Kissei Pharmaceuticals (1991) EP 507 534, JP-prior. 30.3.1991.
Google Scholar
246 Yamaguchi, T. et al. (1997) Preparation of optically active succinic acid derivatives. I. Optical resolution of 2-benzyl-3-(cis-hexahydroisoindolin-2-ylcarbonyl)-propionic acid. Chem. Pharm. Bull. 45, 1518–1520.
10.1248/cpb.45.1518
CAS Web of Science® Google Scholar
247 Yamaguchi, T. et al. (1998) Preparation of optically active succinic acid derivatives. II. Efficient and practical synthesis of KAD-1229. Chem. Pharm. Bull. 46, 337–340.
10.1248/cpb.46.337
CAS Web of Science® Google Scholar
248 Ayerst, McKenna & Harrison Inc. (1981) EP 59 596, CA-prior. 15.10.1981.
Google Scholar
249 Ayerst, McKenna & Harrison Inc. (1981) US 4 391 825, CA-prior. 15.10.1981.
Google Scholar
250 Ayerst, McKenna & Harrison Inc. (1981) US 4 568 693, CA-prior. 2.3.1981.
Google Scholar
251 Ayerst, McKenna & Harrison Inc. (1981) US 4 600 724, CA-prior. 2.3.1981.
Google Scholar
252 Ayerst, McKenna & Harrison Inc. (1981) US 4 705 882, CA-prior. 2.3.1981.
Google Scholar
253 Ayerst, McKenna & Harrison Inc. (1981) US 4 946 987, CA-prior. 2.3.1981.
Google Scholar
254 Sestanj, K. et al. (1984) N-[[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]-N-methylglycine (tolrestat), a potent, orally active aldose reductase inhibitor. J. Med. Chem. 27, 255–256.
10.1021/jm00369a003
CAS PubMed Web of Science® Google Scholar

Citing Literature

Ullmann's Encyclopedia of Industrial Chemistry

Browse other articles of this reference work:

Antidiabetic Drugs (A10)

View previous versions

Oral Antidiabetic Drugs

Antidiabetic Drugs

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Antidiabetic Drugs (A10)

View previous versions

Oral Antidiabetic Drugs

Antidiabetic Drugs

Abstract

References

Citing Literature

References

Related

Information